We sought to examine mechanisms underlying nitroglycerin (NTG) tolerance and "cross-tolerance" to other nitrovasodilators. Rabbits were treated for 3 d with NTG patches (0.4 mg/h) and their aortic segments studied in organ chambers. Relaxations were examined after preconstriction with phenylephrine. In NTG tolerant rabbit aorta, relaxations to cGMP-dependent vasodilators such as NTG (45 +/- 6%), SIN-1 (69 +/- 7%), and acetylcholine (ACh, 64 +/- 5%) were attenuated vs. controls, (90 +/- 2, 94 +/- 3, and 89 +/- 2% respectively, P < 0.05 for all), while responses to the cAMP-dependent vasodilator forskolin remained unchanged. In tolerant aorta, endothelial removal markedly enhanced relaxations to NTG and SIN-1 (82 +/- 4 and 95 +/- 3%, respectively). Other studies were performed to determine how the endothelium enhances tolerance. Vascular steady state .-O2 levels (assessed by lucigenin chemiluminescence) was increased twofold in tolerant vs. control vessels with endothelium (0.31 +/- 0.01 vs. 0.61 +/- 0.01 nmol/mg per minute). This difference was less in vessels after denudation of the endothelium. Diphenylene iodonium, an inhibitor of flavoprotein containing oxidases, and Tiron a direct .-O2 scavenger normalized .-O2 levels. In contrast, oxypurinol (1 mM) an inhibitor of xanthine oxidase, rotenone (50 microM) an inhibitor of mitochondrial electron transport and NG-nitro-L-arginine (100 microM) an inhibitor of nitric oxide synthase did not affect the chemiluminescence signals from NTG-tolerant aortas. Pretreatment of tolerant aorta with liposome-entrapped, pH sensitive superoxide dismutase (600 U/ml) significantly enhanced maximal relaxation in response to NTG, SIN-1, and ACh, and effectively reduced chemiluminescence signals. These studies show that continuous NTG treatment is associated with increased vascular .-O2-production and consequent inhibition of NO. mediated vasorelaxation produced by both exogenous and endogenous nitrovasodilators.
T Münzel, H Sayegh, B A Freeman, M M Tarpey, D G Harrison
Title and authors | Publication | Year |
---|---|---|
Pharmacotherapy of Pulmonary Hypertension
M Humbert, OV Evgenov, JP Stasch |
2013 | |
Pharmacotherapy of Pulmonary Hypertension
M Humbert, OV Evgenov, JP Stasch |
2013 | |
Pharmacotherapy of Pulmonary Hypertension
M Humbert, OV Evgenov, JP Stasch |
2013 | |
Pharmacotherapy of Pulmonary Hypertension
M Humbert, OV Evgenov, JP Stasch |
2013 | |
Pharmacotherapy of Pulmonary Hypertension
M Humbert, OV Evgenov, JP Stasch |
2013 | |
Pharmacotherapy of Pulmonary Hypertension
M Humbert, OV Evgenov, JP Stasch |
2013 | |
Pharmacotherapy of Pulmonary Hypertension
M Humbert, OV Evgenov, JP Stasch |
2013 | |
Pharmacotherapy of Pulmonary Hypertension
M Humbert, OV Evgenov, JP Stasch |
2013 | |
Pharmacotherapy of Pulmonary Hypertension
M Humbert, OV Evgenov, JP Stasch |
2013 | |
Pharmacotherapy of Pulmonary Hypertension
M Humbert, OV Evgenov, JP Stasch |
2013 | |
Pharmacotherapy of Pulmonary Hypertension
M Humbert, OV Evgenov, JP Stasch |
2013 | |
Pharmacotherapy of Pulmonary Hypertension
M Humbert, OV Evgenov, JP Stasch |
2013 | |
Effects of telmisartan or amlodipine monotherapy versus telmisartan/amlodipine combination therapy on vascular dysfunction and oxidative stress in diabetic rats
H Mollnau, M Oelze, E Zinßius, M Hausding, Z Wu, M Knorr, JG Kerahrodi, S Kröller-Schön, T Jansen, C Teutsch, C Foster, H Li, P Wenzel, E Schulz, T Münzel, A Daiber |
Naunyn-Schmiedeberg's Archives of Pharmacology | 2013 |
Tolerance to nitroglycerin through proteasomal down-regulation of aldehyde dehydrogenase-2 in a genetic mouse model of ascorbate deficiency
G Wölkart, M Beretta, MV Wenzl, H Stessel, K Schmidt, N Maeda, B Mayer, A Schrammel |
British Journal of Pharmacology | 2013 |
Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease
A Wang, EW Seely, SA Karumanchi |
Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease | 2013 |
Nitrate therapy and nitrate tolerance in patients with coronary artery disease
T Münzel, T Gori |
Current Opinion in Pharmacology | 2013 |
Rac1-Mediated Effects of HMG-CoA Reductase Inhibitors (Statins) in Cardiovascular Disease
O Adam, U Laufs |
Antioxidants & Redox Signaling | 2013 |
In vitro organic nitrate bioactivation to nitric oxide by recombinant aldehyde dehydrogenase 3A1
S Lin, NA Page, SM Fung, HL Fung |
Nitric Oxide | 2013 |
Left ventricular dysfunction with pulmonary hypertension: part 2: prognosis, noninvasive evaluation, treatment, and future research
AP Kalogeropoulos, VV Georgiopoulou, BA Borlaug, M Gheorghiade, J Butler |
Circulation. Heart failure | 2013 |
Organic Nitrate Metabolism and Action: Toward a Unifying Hypothesis and the Future --- A Dedication to Professor Leslie Z. Benet
NA Page, HL Fung |
Journal of Pharmaceutical Sciences | 2013 |
New Strategies to Advance Pre/Diabetes Care: Integrative Approach by PPPM
MS Mozaffari |
2013 |